Financials data is unavailable for this security.
View more
Year on year Adverum Biotechnologies Inc grew revenues -- from 0.00 to 3.60m while net income improved from a loss of 154.54m to a smaller loss of 117.17m.
| Gross margin | -- |
|---|---|
| Net profit margin | -9,411.10% |
| Operating margin | -10,310.00% |
| Return on assets | -43.66% |
|---|---|
| Return on equity | -76.26% |
| Return on investment | -50.24% |
More ▼
Cash flow in USDView more
In 2023, Adverum Biotechnologies Inc increased its cash reserves by 8.52%, or 6.04m. Cash Flow from Investing totalled 96.88m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 90.90m for operations while cash generated from financing totalled 69.00k.
| Cash flow per share | -5.28 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 6.93 |
|---|---|
| Tangible book value per share | 6.93 |
More ▼
Balance sheet in USDView more
| Current ratio | 5.82 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
